REG - Malin Corp PLC - Poseida Reports Positive Initial Clinical Data

MalinAnnouncement

18/04/2018 07:05

RNS Number : 2402L
Malin Corporation PLC
18 April 2018
 

 
Malin Corporation plc
("Malin" or "the Company")
 
Poseida Therapeutics reports positive initial data for P-BCMA-101 CAR-T stem cell memory product in patients with relapsed/refractory myeloma
 
Dublin-Ireland, 18 April 2018: Malin Corporation plc. (ISE:MLC), an Irish-based global life sciences company, is pleased to note highly encouraging data reported yesterday at the American Association for Cancer Research (AACR) Annual Meeting 2018, by one of its Investee Companies, Poseida Therapeutics.
 
Poseida's P-BCMA-101 is a CAR-T immunotherapy designed to supercharge a patient's own T cells to safely and effectively eliminate tumour cells via B cell maturation antigen (BCMA), which is expressed on essentially all multiple myeloma cells. P-BCMA-101 modifies a patient's T cells using its proprietary non-viral gene delivery system, piggyBac™, which provides several features to increase efficacy while minimising toxicity.
 
P-BCMA-101 is comprised of an exceptionally high proportion of long-lived, self-renewing, multi-potent stem cell memory T cells (Tscm) and the ongoing US study is designed to assess the safety of P-BCMA-101 in up to 40 subjects with relapsed and/or refractory multiple myeloma.  As of April 3, 2018, three patients had been treated in the low dose cohort, with efficacy seen in all three, including at least one partial response lasting more than 10 weeks at time of data cutoff. No dose limiting toxicities were observed.
 
"The lack of cytokine release syndrome (CRS) in any of the three patients in spite of marked efficacy is unprecedented at this dose, which we believe is attributable to multiple differentiated aspects of our technology resulting in a highly purified CAR-T product with a high percentage of cells with a T stem cell memory phenotype," said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida Therapeutics.
 
Dr. Adrian Howd, Chief Executive Officer at Malin said: "CAR-T immunotherapy is an innovative and highly promising approach to cancer treatment. This clinical data is a significant milestone for Poseida following an oversubscribed Series B financing round earlier this month and marks another step towards translating best-in-class gene engineering technologies into lifesaving therapies. Malin owns approximately one third of Poseida and this progress supports our increasing confidence in our assets, their ability to create significant value for our shareholders and underpins our targeted 15% plus growth in Malin's total portfolio value in 2018."
 
A copy of Poseida Therapeutics' press release is available here:
 
http://www.rns-pdf.londonstockexchange.com/rns/2402L_-2018-4-17.pdf
 
 
 
ENDS
About Malin Corporation plc
Malin (ISE:MLC) is an Irish incorporated public limited company. Its purpose is to create shareholder value through selective long-term application of capital and operational expertise to innovative private businesses in the life sciences industry. Through its operational involvement, Malin works with its investee companies to enable them to reach the full potential of their value proposition. For more information visit www.malinplc.com
 
For further information, please contact:
 
Malin Media Relations/IR
Tel: +353 1 901 5717
Email: mediarelations@malinplc.com
 
Lansons (Media Relations Agency)
Eva Murphy
Tel: +44 (0) 20 7490 8828
evam@lansons.com
 
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESIRMRTMBBBBRP